Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.58 |
| ▸ | CNR1 | P21554 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 2/20 | 0.55 |
| ▸ | RAB9A | P51151 | 2/20 | 0.55 |
| ▸ | SPR | P35270 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | PLAAT5 | Q96KN8 | 1/20 | 0.47 |
| ▸ | PLAAT4 | Q9UL19 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8545228 | 0.87 | HDAC3 (0.56) | TAAR1CNR1NPC1RAB9ASPR | |
| SCHEMBL904075 | 0.85 | CTSK (0.54) | TAAR1CNR1NPC1RAB9APLAAT5 | |
| SCHEMBL31457033 | 0.85 | CTSK (0.54) | TAAR1CNR1NPC1RAB9APLAAT5 | |
| SCHEMBL18892410 | 0.84 | NPC1 (0.52) | TAAR1CNR1NPC1RAB9APLAAT5 | |
| SCHEMBL6228914 | 0.84 | LMNA (0.58) | NPC1LMNAHPGD | |
| SCHEMBL1010819 | 0.84 | TAAR1 (0.62) | TAAR1CNR1NPC1RAB9APLAAT5 | |
| SCHEMBL31107125 | 0.84 | SPR (0.72) | TAAR1CNR1NPC1RAB9ASPR | |
| SCHEMBL12720882 | 0.84 | SPR (0.72) | TAAR1CNR1NPC1RAB9ASPR | |
| SCHEMBL18875032 | 0.83 | ALDH1A1 (0.57) | TAAR1CNR1NPC1RAB9ASPR | |
| SCHEMBL30057191 | 0.83 | ALDH1A1 (0.57) | TAAR1CNR1NPC1RAB9ASPR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103880745-A | Chemical synthesis method of 6-bromo-1,2,3,4-tetrahydroisoquinolyl-1-formic acid | UNIV NANTONG | 2014-06-25 | — | — | CN | disclosed |
| US-20130065897-A1 | COMPOUNDS, PREPARATION AND USES THEREOF | PETER MACCALLUM CANCER INSTITUTE (AU) | 2013-03-14 | — | — | US | disclosed |
| EP-2515903-A1 | COMPOUNDS, PREPARATIONS AND USES THEREOF | Peter MacCallum Cancer Institute (AU) | 2012-10-31 | — | — | EP | disclosed |
| WO-2011075784-A1 | COMPOUNDS, PREPARATIONS AND USES THEREOF | PETER MACCALLUM CANCER INSTITUTE (AU) | 2011-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130065897-A1 | COMPOUNDS, PREPARATION AND USES THEREOF | PRF1, GZMB, SERPINB1 | TAAR1 4723/4885CNR1 3810/4885NPC1 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.